公开(公告)号：EP3152235A1

公开(公告)日：2017-04-12

申请号：EP15799237.1

申请日：2015-05-29

申请人： MacroGenics, Inc.

发明人： JOHNSON, Leslie, S. ,  HUANG, Ling ,  CHICHILI, Gurunadh, Reddy ,  SHAH, Kalpana ,  LAM, Chia-Ying, Kao ,  BURKE, Stephen, James ,  LIU, Liqin ,  MOORE, Paul, A. ,  BONVINI, Ezio ,  BARAT, Bhaswati

IPC分类号： C07K16/18

CPC分类号： C07K16/28 ,  C07K16/2803 ,  C07K16/2809 ,  C07K16/2815 ,  C07K16/2827 ,  C07K16/283 ,  C07K16/2878 ,  C07K16/30 ,  C07K2317/31 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/626 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2318/20 ,  C07K2319/00

摘要： The present invention relates to Tri-Specific Binding Molecules, which are multichain polypeptide molecules that possess three Binding Domains and are thus capable of mediating coordinated binding to three epitopes. The Binding Domains may be selected such that the Tri-Specific Binding Molecules are capable of binding to any three different epitopes. Such epitopes may be epitopes of the same antigen or epitopes of two or three different antigens. In a preferred embodiment, one of such epitopes will be capable of binding to CD3, the second of such epitopes will be capable of binding to CD8, and the third of such epitopes will be capable of binding to an epitope of a Disease-Associated Antigen. The invention also provides a novel ROR1-binding antibody, as well as derivatives thereof and uses for such compositions.

摘要翻译： 本发明涉及三特异性结合分子，其是具有三个结合域的多链多肽分子，因此能够介导与三个表位的协调结合。 三特异性结合分子的特征在于具有结合域，其允许其免疫特异性结合：（1）第一癌抗原的表位，（2）第二癌抗原的表位，和（3） 在免疫系统效应细胞的表面上表达的分子，因此能够将免疫系统效应细胞定位于表达癌抗原的细胞，从而有助于杀死这种癌细胞。

公开(公告)号：EP3389714A1

公开(公告)日：2018-10-24

申请号：EP16876434.8

申请日：2016-12-12

申请人： MacroGenics, Inc.

发明人： JOHNSON, Leslie, S. ,  CHICHILI, Gurunadh, Reddy ,  SHAH, Kalpana ,  LA MOTTE-MOHS, Ross ,  MOORE, Paul, A. ,  BONVINI, Ezio ,  KOENIG, Scott

IPC分类号： A61K39/395 ,  C07K16/28 ,  C07K16/30 ,  C07K16/46

CPC分类号： A61K39/395 ,  C07K16/28 ,  C07K16/2803 ,  C07K16/2818 ,  C07K16/30 ,  C07K16/44 ,  C07K16/46 ,  C07K16/468 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/52 ,  C07K2317/53 ,  C07K2317/622 ,  C07K2317/626 ,  C07K2317/64 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/01

摘要： The present invention is directed to bispecific molecules (e.g., diabodies, bispecific antibodies, trivalent binding molecules, etc.) that possess at least one epitope-binding site that is immunospecific for an epitope of PD-1 and at least one epitope-binding site that is immunospecific for an epitope of CTLA-4 (i.e., a "PD-1 x CTLA-4 bispecific molecule"). The PD-1 x CTLA-4 bispecific molecules of the present invention are capable of simultaneously binding to PD-1 and to CTLA-4, particularly as such molecules are arrayed on the surfaces of human cells. The invention is directed to pharmaceutical compositions that contain such PD-1 x CTLA-4 bispecific molecules, and to methods involving the use of such bispecific molecules in the treatment of cancer and other diseases and conditions. The present invention also pertains to methods of using such PD-1 x CTLA-4 bispecific molecules to stimulate an immune response.